Latest Content

Lilly announced a new agreement with the Trump administration to expand access to its GLP-1 therapies, including Zepbound and orforglipron, offering the drugs to Medicare beneficiaries for $50 per month and through Medicaid programs starting in 2026.

Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the industry’s regulated, specialty, and logistics infrastructure.

The addition of Starjemza reinforces Mark Cuban Cost Plus Drugs' effort to expand access to affordable specialty medicines through its transparent cost-plus pricing model, while also enhancing patient support via a new partnership with Medchat.ai.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.

How next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, faster issue resolution, and greater operational efficiency across the global drug distribution network.

In second part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, urges organizations to move beyond one-time vetting toward continuous monitoring, contractual accountability, and shared responsibility for HIPAA compliance.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

Lance Hill, CEO of Within3, discusses how AI-driven decision support tools are helping pharmaceutical companies achieve launch excellence while maintaining regulatory compliance and data integrity.

The investment is aimed at boosting oral medicine manufacturing capacity.

In the final part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, emphasizes that as digital tools become central to patient support, there is value to balancing technology with empathy.